The method, in full.

A — Separation

Chromatography

• Mode: reversed-phase HPLC, C18 column (core-shell, 2.6–5 µm, 4.6 × 150 mm class).
• Mobile phase: gradient, water/acetonitrile with 0.1% trifluoroacetic acid.
• Detection: UV at 214 nm (peptide bond absorbance), diode-array detector; 280 nm recorded where aromatic residues allow a second check.
• Platform method: one platform gradient family — validation records published with method v1.0 — covers most single peptides; peptide-specific adjustments (gradient slope, run time) are recorded per analyte and stated on the CoA.

B — What the numbers mean

Purity and quantity

• Purity is chromatographic purity: main-peak area as a percentage of total integrated peak area at 214 nm, solvent front excluded. It is not a mass-balance purity, and the CoA says so.
• Quantity (mg/vial) is measured against a reference standard: pharmacopoeial where one exists (semaglutide, tirzepatide, liraglutide — retatrutide, cagrilintide and survodutide have no monograph), otherwise an in-house working standard — a ≥98% research-grade or custom-synthesis lot characterized by amino acid analysis (subcontracted) and UV extinction at 214 nm calculated from sequence.
• Identity in the base test is presumptive: retention-time co-elution with the reference standard under the stated method. Mass-spectral confirmation is an optional add-on via a partner laboratory until our own LC-MS is commissioned.

C — Limits, stated plainly

What this method cannot tell you

• It cannot confirm molecular identity by mass — co-elution is strong evidence, not proof. Order the MS add-on when identity is the question.
• It does not measure sterility, endotoxin load or heavy metals (planned as separate services; until then, we say "not tested", never "passed").
• It describes the vial received — not the batch it allegedly came from, and not the vendor's whole production.
• Chromatographic purity can hide co-eluting impurities; where the DAD spectrum suggests one, the CoA flags it.

D — Quality

How we keep ourselves honest

• System suitability before every sequence; blanks and standard bracketing within it. Failures void the run, not the report.
• Duplicate preparation on every quantification; both values on the CoA.
• Blind calibration round against the market-leading laboratory before launch, published in full — and repeated periodically after launch.
• ISO/IEC 17025 accreditation: application planned in year one. Until granted, we do not claim it — and we publish our progress in the build log.
• Errors: when we get one wrong, the corrected CoA is published over the original with a visible correction note. The original stays visible. That is the deal.

E — Scope

Peptides only

We analyze research peptides. We do not accept anabolic steroids, growth hormone, or any controlled substance — from anyone, at any price. Out-of-scope samples are destroyed on receipt and the order refunded minus handling. This is a hard policy, not a pricing tier.